edicinal preparations containing antigens or antibodies (A61K39)

A61K39/012 - Viral antigens(12)
A61K39/018 - (4)
A61K39/02 - Bacterial antigens(275)
A61K39/07 - Bacillus(32)
A61K39/085 - (66)
A61K39/09 - Streptococcus(117)
A61K39/095 - (67)
A61K39/102 - (47)
A61K39/104 - (27)
A61K39/106 - (36)
A61K39/108 - (76)
A61K39/112 - (70)
A61K39/114 - (3)
A61K39/116 - (90)
A61K39/118 - (32)
A61K39/12 - Viral antigens(319)
A61K39/125 - (16)
A61K39/13 - Poliovirus(78)
A61K39/135 - (71)
A61K39/145 - (161)
A61K39/155 - (31)
A61K39/165 - (18)
A61K39/17 - Newcastle disease virus(57)
A61K39/175 - (15)
A61K39/187 - (19)
A61K39/193 - (6)
A61K39/20 - Rubella virus(50)
A61K39/205 - (40)
A61K39/215 - (22)
A61K39/225 - (15)
A61K39/235 - (29)
A61K39/245 - (28)
A61K39/25 - Varicella-zoster virus(19)
A61K39/255 - (18)
A61K39/265 - (23)
A61K39/275 - (31)
A61K39/285 - (18)
A61K39/29 - Hepatitis virus(173)
A61K39/295 - (89)
A61K39/35 - Allergens(59)
A61K39/36 - From pollen(14)
A61K39/38 - Antigens from snakes(91)
A61K39/385 - (82)
A61K39/395 - (1191)
A61K39/40 - Bacterial(101)
A61K39/42 - Viral(84)

Immunity-inducing means // 2614386
FIELD: biotechnology.SUBSTANCE: invention refers to production of means containing at least one polypeptide selected from SEQ ID NO: 4, 2, 8, 10 and 12, and/or recombinant vector(s), comprising polynucleotide(s) encoding at least one polypeptide, as the active ingredient(s), and can be used in medicine. The resulting means is used for efficient induction of T-cell immunity against malignancies expressing KATNAL1.EFFECT: invention allows to obtain antigen-presenting cells presenting the polypeptide obtained from KATNAL1, and to effectively induce cytotoxic cells against KATNAL1, which is efficient as a therapeutic agent against malignant neoplasms expressing KATNAL1.7 cl, 3 dwg, 3 ex

Stable liquid pharmaceutical preparations of fused protein tnfr: fc // 2614257
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.50 cl, 1 dwg, 17 tbl, 3 ex

Alpha-v beta-8-binding antibodies // 2614252
FIELD: pharmacy.SUBSTANCE: antibodies with high affinity for β8-subunit αvβ8 proposed. Pharmaceutical composition comprising such antibodies, and methods of their application are also described. The proposed group of inventions can be used in medicine.EFFECT: improved antibody properties.23 cl, 14 dwg, 19 ex
ethod for producing a complex shigellosis drug // 2614123
FIELD: pharmacy.SUBSTANCE: method involves mixing of equal weight amounts of modified lipopolysaccharide Shigella flexneri 2a and exopolysaccharide Shigella sonnei in the buffered solution of the following composition: 0.2 M NaCl, 0.05 M Tris, 0.25% sodium deoxycholate, pH 8.3, at 80°C, followed by dialysis against the same buffered solution without sodium deoxycholate and then against deionized water followed by lyophilization. In this case the modified lipopolysaccharide Shigella flexneri 2a lipid A is partially O-deacylated. The said modified lipopolysaccharide Shigella flexneri 2a is obtained as a result of selective alkaline hydrolysis of the original lipopolysaccharide Shigella flexneri 2a.EFFECT: invention provides a drug with low toxicity, high efficiency and bimodal specificity.2 dwg, 3 tbl, 5 ex

ethod of producing human immunoglobulin // 2614119
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Group of inventions is described, which involves method of producing human immunoglobulin and preparation of human immunoglobulin, obtained using said method. Method includes stage of dissolving of Cohn component I+II+III or Cohn component II+III in water for injections; deposition with caprylic acid or caprylate; first stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (2), to 5.2, cleaning by anion-exchange chromatography and obtaining eluating solution; deposition of IgM, including control of conductivity of eluating solution obtained at step (3), up to 500–1,000 µS/cm by means of water and further bringing pH to 6.0–7.3,with subsequent settling for 1–2 hours, filtration and filtrate collection; second stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (4) to 5.6, subsequent purification by anion-exchange chromatography and collection of eluating solution; production of human immunoglobulin by dialysis of eluating solution obtained at step (5), by ultrafiltration, obtaining pharmaceutical form and inactivation of viruses.EFFECT: invention extends range of methods for producing human immunoglobulin.9 cl, 2 dwg, 3 tbl, 2 ex

Bacteriophages, phage peptides and methods for application thereof // 2614114
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Described is bacteriophage F510/08, comprising genome, which contains nucleic acid sequence SEQ ID NO: 4. Bacteriophage shows activity upon Pseudomonas aeruginosa. Invention also describes versions of pharmaceutical composition containing such bacteriophage, and methods of therapy for treatment and prevention of bacterial infection.EFFECT: presented group of inventions can be applied in medicine.23 cl, 327 dwg, 7 tbl, 7 ex

Conjugated protein-active agents and methods of their production // 2613906
FIELD: pharmacy.SUBSTANCE: conjugated protein active agent has an amino acid motif which can be recognized via isoprenoid transferase, wherein the active agent is covalently bound via at least one linker with izosubstrate, where the izosubstrat contains at least one isoprene unit and is a recognizable isoprenoid transferase, which is attached to a cysteine residue of the amino acid motif. The invention also relates to a composition comprising conjugates, and to methods for preparing conjugates and compositions.EFFECT: use of the conjugates for the delivery of the active agent into target cells with a high selectivity.16 cl, 27 dwg, 5 ex

Liquid composition of long-acting alpha interferon conjugate // 2613905
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to the field of pharmacy and medicine and relates to a liquid composition (options), in which the long-acting INF conjugateα and the immunoglobulin Fc-fragment are covalently linked by a non-peptidic polymer, and includes a stabilizer with a buffer, sugar alcohol, a nonionic surfactant and an isotonic agent; at that, it does not contain human serum albumin and other potential factors harmful for the organism. The inventive method for liquid composition production and a stabilizer are also stated.EFFECT: group of inventions provides excellent storage stability of long-acting INF conjugatesα with improved durability and stability in vivo, can be safely stored for a long period of time.17 cl, 1 dwg, 6 ex, 12 tbl
Production method of brucellar monospecific serum anti-melitensis // 2613901
FIELD: veterinary medicine.SUBSTANCE: provide the immunizations of rabbits with a single dose of B. melitensis strain. The rabbits immunization is carried out subdermally in the dewlap area with suspension of 1 ml volume, which contains:. 200 million MK inactivated culture of B. melitensis strain 16M with adjuvant MONTANIDE™ ISA 61 VG. At the 14th-16th day the trial blood collecting is conducted, and at the 21st-45th day the three-time blood collecting is carried out and at the 60th day it is dehematized. The serum is obtained and inactivated at 60-65°C during 1-1.5 hours. The cross adsorption with bacteriological weight of B. abortus 544 strain is carried out, obtained by culture growing within 70-72 hours. Centrifuge with cooling the residue during 24-26 hours, adding to the residue the physiological solution for obtaining the bacterial weight in the amount of 3.5-3.7×109 pfu per 10 ml of serum. Further incubate at 37°C for 2 hours and restore the serum by centrifugation with further preserving and packaging.EFFECT: utilisation of this method allows the use the inactivated Brucella culture to produce a monospecific serum, and take blood from each of the rabbits for at least four-times, increasing the amount of the resulting serum.2 ex, 8 tbl

ethod for production "ks" swine fever vaccine nanocapsules in sodium alginate // 2613795
FIELD: biotechnology.SUBSTANCE: method includes dilution of 55 mg of "KS" vaccine were dissolved in 3 ml of petroleum ether and dispersed into a sodium alginate suspension in petroleum ether containing 550 mg of this polymer in the presence of 60 mg of E472s preparation as surfactant while stirring at 1000 rpm, then 5 ml of ethyl acetate is added, the precipitate is filtered and dried at room temperature.EFFECT: simplification and acceleration of "KS" vaccine nanocapsules production process, increasing their output by weight.1 dwg, 1 tbl, 3 ex
Vaccine for protection of ruminant animals against pneumonia caused by pasteurella multocida // 2613672
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary science and is intended for protection of ruminant animals against pneumonia caused by P. Multocida. Disclosed method involves introduction of vaccine containing living attenuated bacteria P. multocida, in upper parts of airway of ruminant animal by intranasal vaccine spraying.EFFECT: disclosed method is highly effective for protection of ruminant animals against pneumonia caused by Pasteurella multocida.5 cl, 5 tbl, 2 ex

Antibody for blys // 2613422
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. The antibody for BLyS is stated. The invention also relates to the DNA molecule encoding the said antibody, the expression vector and the host cell to produce the said antibody. It is also proposed to use BLyS antibodies in a pharmaceutical composition and in the method for prevention and/or treatment of diseases caused by excessive proliferation of B-cells, such as systemic lupus erythematosus. The invention allows binding to BLyS with high affinity and inhibition of binding to its receptor with high BR3 specificity.EFFECT: invention adds a new BLyS antibody concept to biochemistry with a proposal to use the antibody for prevention and/or treatment of diseases caused by excessive proliferation of B-cells.15 cl, 10 dwg, 4 tbl, 10 ex

High-affinity human antibodies to cytomegalovirus (cmv) gb protein // 2613421
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, namely to monoclonal antibody or its antigen-binding fragment, which specifically binds protein gB of cytomegalovirus (CMV). Invention also discloses nucleic acid coding above antibody, host cell producing above antibody, pharmaceutical composition for treating CMV or induction of resistance to CMV containing said antibody. Invention discloses method of producing above antibody and its antigen-binding fragment, their use for treating CMV or increasing resistance to CMV.EFFECT: invention is capable of specific binding with CMV, which provides effective treatment of diseases associated with CMV protein expression.11 cl, 4 dwg, 2 tbl, 5 ex
Combined vaccine with whole-cell pertussis component // 2613295
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used for production of combined liquid vaccine. Fully liquid stable combined vaccine contains antigens of diphtheria (D), tetanus (T), whole cell pertussis (wP), IPV and Haemophilus influenzae (Hib). IPV antigens are Salk strains, selected from group of Mahoney strains type 1, MEF type 2 and Saukett type 3 or Sabin, selected from group Sabin 1 or 2. Antigen Hib is conjugated with protein selected from group comprising tetanus anatoxin, diphtheria anatoxin, CRM 197 and outer membrane protein of Neisseria meningitides. Wherein D is present in amount of about 1-40 Lf, T is present in amount of about 1-25 Lf, wP is present in amount of about 1–30 IOU per 0.5 ml and Hib b is present in amount of about 1–20 mcg per 0.5 ml. Group of inventions also relates to method of producing said vaccine and method for inducing immune response to any antigen, selected from group D, T, P, Hib, Hep or IPV, in individual. Application of this group of inventions enables to obtain fully liquid multicomponent vaccine with optimized dose of antigens, wherein in declared vaccine anatoxins of D, T are adsorbed on suitable adjuvant based on aluminium, while Hib component is not adsorbed on any of adjuvant, in vaccine 2-phenoxyethanol is used as preservative.EFFECT: procedure for producing individual antigens is developed in vaccine composition with improved antigenicity, applicability and stability, which enables using component Hib b not in separate lyophilized form by formation of vaccine immediately before its introduction, but directly in liquid state of vaccine.20 cl, 4 ex, 5 tbl
ultivalent composition of pneumococcal polysaccharide-protein conjugate // 2613148
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns a multivalent immunogenic composition comprising 13 different polysaccharide-protein conjugates together with a physiologically acceptable medium, wherein each of the conjugates comprises a protein-polysaccharide capsular polysaccharide from a single serotype of Streptococcus pneumoniae, conjugated to the carrier protein CRM197, and the capsular polysaccharides are prepared from 12 serotypes, selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F and serotype 22F or 33F. The group of inventions also relates to a pharmaceutical composition for immune response induction to the capsular polysaccharide conjugates of Streptococcus pneumoniae.EFFECT: induction of IgG titers and functional antibodies activity that are equivalent or better compared with the Prevnar 13 vaccine for all 13 serotypes.7 cl, 3 ex

phosph1 peptides and vaccines containing them // 2612905
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to anti-tumor vaccines based on epitope peptides MPHOSPH1 and can be used in medicine. Peptide is obtained consisting of amino acid sequence SEQ ID NO: 120. Peptide can contain replacement of C- and/or N-terminal amino acid of above sequence to leucine or methionine. Obtained epitope peptide has ability to induce cytotoxic T-lymphocytes (CTL) in presence of antigen presenting cell (APC) carrying HLA-A*0201 or HLA-A*0206.EFFECT: invention allows inducing immune response against malignant tumor expressing MPHOSPH1 in individual, HLA antigen of which is HLA-A*0201 or HLA-A*0206.14 cl, 6 dwg, 3 tbl, 1 ex

H1n1 influenza virus antigens with wide spectrum of activity, optimized using computer tools // 2612900
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Production of optimized HA polypeptides of influenza virus H1N1 is described, causing immune response with wide spectrum of activity in relation to influenza virus H1N1 isolates. Optimized HA polypeptides were developed by series alignments of HA protein sequences and subsequent formation of consensus sequences based on structure of certain viruses H1N1 recovered from 1918 at 2011. Invention also describes composition, fused proteins and VLP containing HA polypeptides. Invention also describes sequence of nucleic acids, subjected to optimization of codons coding HA polypeptides and methods for inducing immune response against influenza virus in subject.EFFECT: disclosed group of inventions can be used in medicine.23 cl, 7 dwg, 3 ex

ethod for preparing composition of immunoglobulins // 2612899
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Disclosed is method for producing composition containing IgM immunoglobulins from plasma fractions. Also described is antibody preparation produced by such method, and use of this preparation for therapy of patients or preparing medicine for treating immunological disorders and bacterial infections.EFFECT: method involves providing plasma fraction in form of solution containing immunoglobulins, mixing solution with octanoic acid, treatment of mixed solution in vibromixer for deposition of contaminating proteins, and separation of deposited proteins from solution to obtain composition containing IgM from immunoglobulins.30 cl, 1 dwg, 11 tbl, 9 ex
ethod for treatment of locally spread unresectable esophageal cancer // 2612090
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for treatment of locally spread unresectable esophageal cancer. For this purpose in conditions of procedure room after processing chest skin with antiseptic solution patients receive intradermally by 0.3 ml of autologous dendritic-cell vaccine, two injections from each side of chest approximately between III and IV, IV and V ribs. Dose constitutes 5,000,000 dendritic cells. 2 weeks after introduction of first vaccine second dendritic-cell vaccine is introduced in the same dose. 2 weeks after introduction of second vaccine third dendritic-cell vaccine is introduced in total dose 10,000,000 dendritic cells. 2 weeks after third introduction of vaccine fourth dendritic-cell vaccine is introduced in total dose 10,000,000 dendritic cells. During the entire course of vaccine therapy patients receive 30,000,000 cells.EFFECT: invention makes it possible to increase duration and to improve quality of life in patients with locally spread unresectable esophageal cancer.1 ex
ethod of prevention of colibacillosis in calves // 2612081
FIELD: agriculture.SUBSTANCE: invention relates to the field of veterinary medicine and is intended for prevention of colibacillosis in calves. The immunization of down-calving cows is performed 1.5-2 months before the delivery with the vaccine against colibacillosis of animals Coli-Vack K88, K99, 987P, F41, TL- and TC-anatoxins twice with an interval of 15 days, the first dose is 10 cm3, the second is 15 cm3. The visceral novocaine blockade on L.G. Smirnov is performed to calves received from these cows within 1-2 hours after birth and on the 7th day of life.EFFECT: method increases the level of specific and non-specific humoral and cellular immunity of calves; reduces the incidence of colibacillosis.3 tbl, 1 ex

Enterosorbent for directed sorption of cholera exotoxin, dosage form of enterosorbent for directed sorption of cholera exotoxin // 2611356
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, particularly, to production of the enterosorbent for directed sorption cholera exotoxin. Enterosorbent for directed sorption cholera Exotoxin, obtained by immobilization by method of adsorption antitoxic anticholeraic immunoglobulin G, recovered from blood serum of animals immunized with cholera toxin, on microparticle size 200–300 nm of pre-treated acid-soluble chitosan in ratio of 0.08–0.1:1. Solid dosage form of enterosorbent for directed sorption cholera exotoxin.EFFECT: above solution enables to obtain a medicinal agent for directed sorption of cholera exotoxin and ensure reduction or complete neutralization of action of cholera exotoxin.5 cl, 5 tbl, 6 ex

Conditionally replicating cytomegalovirus as vaccine against cmv // 2611198
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. Conditionally defective replication of Cytomegalovirus (CMV) and compositions containing it are disclosed for use as vaccine, method of production and use of said CMV in preparing drug and in medicine and application of specified composition for inducing immune response against CMV in patient. Proposed CMV conditionally defective by replication contains pentamerous gH-complex including UL128, UL130, UL131, gH and gL, and two nucleic acid coding fused protein. First fused protein consists of IE1/2 and destabilizing protein, second fused protein is from UL51 and destabilizing protein. Destabilizing protein is FK506-binding protein (FKBP) or its derivatives with amino acid substitutes F36V and L106P. Proposed CMV has restored expression of gH-complex by mutation correction UL131 and it has no wild type IE1/2 and UL51.EFFECT: proposed CMV can be used in medicine as component of vaccines based on attenuated strains of CMV, generating neutralizing antibody and causing T-cell immune responses.19 cl, 39 dwg, 2 tbl, 7 ex

Pharmaceutical composition for cancer treatment and/or prevention // 2611197
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to biochemistry, namely to an antibody or fragment thereof, wherein the antibody or fragment thereof specifically binds to CAPRIN-1 protein, DNA, its encoder, as well as to a conjugate of the said antibody or fragment thereof with an antitumor agent. The invention also relates to pharmaceutical composition and pharmaceutical combination for cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface, as well as to a method for cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface using the above antibody or fragment thereof.EFFECT: invention enables efficient cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface.8 cl, 7 ex

Antigen-binding molecules, which bind egfr, vectors coding them and use thereof // 2610688
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology and immunology. Invention discloses isolated polynucleotides coding variable regions of light and heavy chains of antibody to human EGFR; anti-EGFR antibody and antibody fragment; as well as vector, host cell and method of producing anti-EGFR antibody or its fragment. There are disclosed: composition containing anti-EGFR antibody or its fragment, use thereof, as well as use of antibody and its fragment for treating disorders characterized by EGFR overexpression. Besides, method of detecting presence of EGFR in sample using disclosed antibodies is described.EFFECT: present invention can find further application in treating EGFR-mediated diseases.70 cl, 29 dwg, 38 tbl, 5 ex

Antibody blocking agr2, and use thereof // 2610665
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. AGR2 blocking monoclonal antibody is described and in particular humanized monoclonal antibody for AGR2 blocking. Invention also describes pharmaceutical composition containing antibody, production method thereof and application of antibody for blocking tumor growth and metastasis.EFFECT: disclosed group of inventions can be used in medicine.20 cl, 28 dwg, 11 ex

Antibodies to folic acid receptor 1, their immunoconjugates and application // 2610663
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. Humanized antibody and its antigen-binding fragment are disclosed, specifically binding to human folic acid receptor 1 (FOLR1) and characterized by amino acid sequences of sections determining complementarity with antigen (CDR). Method of producing humanized antibodies under invention; immunoconjugates with cytotoxic agent; pharmaceutical composition; diagnostic composition; kits; methods of inhibiting tumor growth and method of treating cancer are also disclosed. Isolated polynucleotides coding variable domains of disclosed antibodies; vectors containing them and host cells are also disclosed.EFFECT: antibody under invention is humanized form of mouse antibody Mov19 and it can find further application in therapy of diseases characterized by high expression of FOLR1.69 cl, 19 dwg, 4 tbl, 19 ex

Cd37 binding molecules and immunoconjugates // 2610662
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. Antibodies are described, which specifically bind to human CD37 and macaque CD37. Immunoconjugate, consisting of antibody and cytotoxic agent, and application of antibody or immunoconjugate for treating oncological disease are also described.EFFECT: disclosed group of inventions can be used in medicine.25 cl, 32 dwg, 11 tbl, 17 ex
ethod of treating pathological syndrome and drug of central and peripheral action for treating pathological syndrome // 2610438
FIELD: medicine.SUBSTANCE: invention relates to medicine and represents method of treating obesity, nicotine addiction and reduction of alarm, while smoking cessation by administering drug central and peripheral action in body, which is based on activated potentiated form of antibodies. Disclosed method is characterized by that drug contains activated potentiated form of antibodies to human cannabinoid receptor in form of activated potentiated aqueous or aqueous-alcoholic solution, obtained during successive multiple dilution of matrix solution in water or aqueous-alcohol solvent and intermediate external mechanical action.EFFECT: higher efficiency of treating obesity, nicotine addiction and reduction of alarm, while smoking cessation.17 cl, 12 tbl, 7 ex

Pharmaceutical composition for treating and/or preventing malignant growth // 2610428
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, namely to antibody or its fragment, which possess immune responsiveness in relation to protein CAPRIN-1. Invention also discloses antibody, which specifically binds to CAPRIN-1, pharmaceutical composition containing said antibody or its fragment or conjugate for treating or preventing malignant tumors, associated with CAPRIN-1, DNA, coding said antibody. Method of treating or preventing malignant tumors, associated with CAPRIN-1, using disclosed antibody is proposed.EFFECT: invention enables specific binding to CAPRIN-1, which enables effective treatment of malignant tumor associated with expression of CAPRIN-1.8 cl, 8 ex

Vaccine compositions against human papilloma virus (hpv), containing aluminium adjuvant, and methods of production thereof // 2610174
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used for producing human papilloma virus vaccine. Vaccine composition against human papilloma virus includes: a) therapeutically effective amount of virus-like particles (VLP) HPV, adsorbed on aluminium adjuvant; b) mannitol and saccharose, c) optionally salt. Wherein composition contains: 1) virus-like particles HPV of at least one type, adsorbed on aluminium adjuvant, present in concentration equal to 10-200 mcg/ml, wherein virus-like particles are selected from group, consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73 and HPV82; and 2) from approximately 1 % to approximately 10 wt/vol. of mannitol; and 3) from approximately 0.5 % to approximately 10 % of sucrose. Composition is frozen or lyophilized and composition is stable at storage during 1 month at 25 °C after stress caused by process of lyophilization or freezing-thawing. Group of inventions also relates to methods of producing said vaccine.EFFECT: use of given inventions enables to obtain solid preparation of vaccine HPV (frozen or lyophilized) containing combination of excipients mannitol and saccharose, providing preservation of antigenicity of lyophilized vaccine preparation.21 cl, 9 ex, 3 tbl, 15 dwg
ethod for prevention of larval stage of echinococcosis alveolaris // 2609858
FIELD: medicine.SUBSTANCE: invention relates to medicine and deals with method of prevention of larval stage of echinococcosis alveolaris, which includes introduction of cellular antigen from protoscolexes of Echinococcus multilocularis, where simultaneously with cellular antigen from protoscolexes of E.multilocularis biopreparation, which represents membranous fraction of epimastigotes Trypanosoma cruzi cells, is introduced subcutaneously.EFFECT: invention ensures development of protective immune reaction, which prevents from further infection.2 ex, 2 tbl
ethod for obtaining erythrocyte antigen for diagnostics of nectobacteriosis in animals // 2609771
FIELD: medicine, pharmacology.SUBSTANCE: antigen fraction is obtained by cultivation of industrial strain Fusobacterium necrophorum "0-1" VIEV with further separation of bacterial mass and resuspension with 0.8-1.2% dezmol solution to concentration 4-10 bil/ml of microbial bodies, after that, heated at temperature 93-98°C for 55-65 min, and mixture is centrifuged at 1.5-3.0 thousand g, for 20-30 min. Formalin in final concentration 0.3-0.4% is added to supernatant and incubated at room temperature for 10-15 days. After that, formalised erythrocytes, taken in final concentration 9-12%, are added to reaction mixture, and target product is obtained by incubation of reaction mixture with formalised erythrocytes at 40-46°C for 1.5-2 hours with their further cooling to room temperature and washing.EFFECT: obtaining erythrocyte antigen for diagnostics of necrobacteriosis in animals makes it possible to increase storage term of target product with preservation of its specific activity.4 cl, 7 ex

Pharmaceutical composition for preventing and/or treating hiv disease in humans // 2609769
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and can be used for preventing and/or treating HIV-disease in human, who requires it. Oral pharmaceutical composition contains mixture of coarse antigen, which contains one or more epitopes of HIV proteins Gag and/or Pol, and non-pathogenic recombinant bacterium, selected from group consisting of bacteria Lactobacillus and BCG. Kit for preventing and/or treating HIV-disease in humans is also disclosed.EFFECT: group of inventions provides prevention and/or treatment of HIV-disease in human by capacity of said composition to provide “Ts” anti-HIV immune tolerance, as result specified virus is not able to replicate in host organism.11 cl, 16 dwg, 1 tbl, 1 ex
ethod of production of rabies diagnostic serum // 2609766
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to immunology, and can be used for production of rabies diagnostic serum. For that immunization of animals-producers with antigen material and adjuvant is made. As adjuvant mixture of lanolin and polyethylsiloxane liquid is used, taken in weight ratio 1:2–9, respectively, immunomodulator immunofan in amount of 0.8–1.2 ml per one animal is additionally used. Immunization is performed 5 times, wherein at first three times every 20–24 hours antigen is introduced together with adjuvant, taken in weight ratio 1:0.8–1.0 in amount of 10–14 ml of mixture of antigen with adjuvant per one animal and simultaneously – immunofan. Then 12–16 days later antigen is introduced in amount of 5–7 ml of antigen per one animal and simultaneous immunofan, then 7–8 days later antigen is introduced in amount of 5–7 ml of antigen per one animal. Besides, method of producing rabies diagnostic serum uses polyethyl siloxane liquid PES-2 or PES-3 as polyethylsiloxane liquid, and antigen material is "sheep" strain of rabies virus VGNKI and reference strain CVS.EFFECT: application of given method allows to increase target product quality due to increased specific activity of serum.4 cl, 5 ex

ethod for production of "ks" vaccine nanocapsules from swine fever covered by sodium carboxymethylcellulose // 2609741
FIELD: medicine.SUBSTANCE: invention refers to the method for preparation of "KS" vaccine nanocapsules against swine fever. The peculiarity of the said method is that the "KS" vaccine is dissolved in petroleum ether, and then dispersed into a suspension of sodium carboxymethylcellulose in petroleum ether in the presence of E472s preparation as a surfactant while stirring 1000 rev/min, then butyl chloride is added, nanocapsules precipitation is filtered and dried at room temperature.EFFECT: invention provides simplification and acceleration of the production process of the "KS" vaccine nanocapsules, as well as increase of their yield by weight.1 dwg, 3 ex

Respiratory syncytial virus antigenic compositions and methods // 2609661
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. Disclosed are immunogenic compositions in form of a multilayer film, containing B-cell (antibody) epitope of RSV-G169-191 and additionally T-cell epitope of RSV-M281-95 proteins of respiratory syncytial virus (RSV), wherein epitope of RSV-G is located in outer layer of film. Said film comprises two or more layers of polyelectrolytes, where adjacent layers contain oppositely charged polyelectrolytes, containing polycationic substance or polyanionic substance, having molecular weight greater than 1,000, and at least 5 charges per molecule. In addition, described is a method for immunisation against RSV.EFFECT: compositions according to present invention provide increased B-cell response against RSV and can be used in preventing RSV infection.17 cl, 21 dwg, 5 tbl, 19 ex

Composition containing antibody // 2609658
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is a pharmaceutical composition for treating angiogenic diseases, comprising an antibody, which binds with VEGF, in an arginine acetate buffer, pH 4.5–6.0, and a surfactant, where antibody is bevacizumab.EFFECT: invention enables to obtain a stable aqueous pharmaceutical composition containing a therapeutically effective amount of an antibody.70 cl, 4 dwg, 8 tbl

ethod of inhibiting leucocidin ed toxicity of staphylococcus aureus in individual // 2609650
FIELD: pharmaceutics.SUBSTANCE: invention relates to method of inhibiting leucocidin ED toxicity of Staphylococcus aureus in individual. Described method involves: selection of individual infected with S. aureus, and introduction of CCR5 antagonist to subject selected in effective amount for inhibiting cytotoxicity of leucocidin ED of S. aureus in individual.EFFECT: invention can be used for prevention and treatment of Staphylococcus aureus infection.5 cl, 6 dwg, 2 tbl, 6 ex

Anti-cd40-antibodies and methods of application // 2609647
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. An isolated antibody or antigen-binding fragment that is bound to human CD40 and acts as agonists of CD40 is described. An isolated polynucleotide encoding an isolated antibody or antigen-binding fragment thereof, an expression vector containing an isolated polynucleotide isolated host cell to produce an antibody or antigen-binding fragment thereof are described. A composition for treatment or alleviation of a disease or disorder associated with CD40, comprising a physiologically acceptable carrier and a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof is presented. Methods for treatment or alleviation of symptoms for patients having cancer, reduction of symptoms for patients having autoimmune diseases, alleviation of symptoms for patients having inflammatory diseases, including composition injection are presented.EFFECT: invention increases the variety of CD40 antagonists.29 cl, 18 dwg, 1 tbl, 3 ex

Expression system // 2609645
FIELD: pharmaceutics.SUBSTANCE: invention concerns expression systems, including protein coding polynucleotides. Expression system comprises first polynucleotide coding at least one protein, peptide or their version, which induces T-cell response, and second polynucleotide coding at least one protein, peptide or their version, which induces B-cell response against pathogen. Invention also relates to mixtures of proteins coded by expression system and cells containing expression system or mixture of proteins and pharmaceutical compositions containing expression system or mixture of proteins. Invention also concerns nucleotide structures, including, mainly consisting of polynucleotide coding modified hemagglutinin (HA) of influenza virus.EFFECT: expression system, polynucleotides, proteins, cells and pharmaceutical compositions are applicable in preventing or treating infections.15 cl, 13 dwg, 1 tbl, 5 ex

High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative // 2609627
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. A humanized IgG type monoclonal antibody that binds to human 17A interleukin is proposed. The antibody contains variable domains as a combination of VHH derivative with a light chain VL variable domain. The said VHH derivative contains amino acid substitutions at positions 44 and 45 (according to Kabat numbering). The invention also refers to DNA encoding the antibody, expression vector, cell line and a method for production of the said antibody. Furthermore, a pharmaceutical composition for treatment of IL-17A-mediated disease or disorder, comprising the antibody is proposed.EFFECT: invention allows to obtain antibodies with high affinity and enhanced aggregation stability.15 cl, 17 dwg, 6 tbl, 19 ex
ethod for chronic rhinitis treatment by selective denervation of nasal mucosa // 2609289
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, otolaryngology and can be used to treat patients with chronic rhinitis. Selective denervation of the nasal cavity mucous membrane is performed using intramucosal injection of type A botulinum toxin in the patient's inferior turbinate with application of local anesthesia. Injection is carried out under the control of endoscope by means of an endoscopic fine needle, 40 units of botulinum toxin are injected into the medial wall of each inferior turbinate along its medium line covering front, middle and rear sections, at four points on each side. After injection, 30-minute loose front swabbing by gauze turundas is performed.EFFECT: method provides lasting clinical results with low invasiveness and absence of side effects of a single procedure, even with application of botox alone.2 ex

Immunogenic compositions // 2608905
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to immunology, and can be used for producing immunogenic composition. Immunogenic composition contains a) conjugate, which is capsular saccharide GBS of serotype Ia conjugated with protein-carrier; b) conjugate, which is capsular saccharide GBS of serotype Ib conjugated with protein-carrier; and c) conjugate, which is capsular saccharide GBS of serotype III conjugated with protein-carrier, where (i) each capsular saccharide GBS is present in an amount of 5 mcg, 10 mcg or 20 mcg per dose unit, (ii) protein-carrier in a), b) and c) is diphtheria or CRM197 toxoid, and iii) immunogenic composition does not contain an adjuvant based on aluminium salts.EFFECT: use of given composition of immunogenic compositions with effective amounts of polysaccharides GBS of type Ia, Ib and III, conjugated with CRM197, makes it possible to use it as a vaccine for preventing GBS infection in human body.14 cl, 4 dwg, 21 tbl

Humanised antibodies to liv-1 and use thereof for treating cancer // 2608646
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, particularly to humanised antibody, which specifically binds to LIV-1, as well as a nucleic acid coding mature variable heavy chain region and to nucleic acid coding mature variable light chain region of said antibody. Also disclosed is a conjugate of said humanised antibody with cytotoxic or cytostatic agent for treatment or preventive treatment of cancer, associated with expression of LIV-1. Invention also relates to a method of treatment or preventive treatment of a patient, having cancer or at risk of cancer associated with expression of LIV-1, as well as to a pharmaceutical composition for treatment or preventive treatment of cancer associated with expression of LIV-1.EFFECT: invention provides effective treatment or preventive treatment of cancer associated with expression of LIV-1.21 cl, 28 dwg, 8 tbl, 3 ex

Anti c-met receptor protein antibodies // 2608644
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is an antibody or its antigen-binding fragment which specifically binds to human c-Met protein. Also described is an isolated polynucleotide coding said antibody, an expression vector containing said polynucleotide, a host cell containing said vector. Disclosed is a method of producing a recombinant antibody by culturing described host cell. Disclosed is a pharmaceutical composition for treating cancer and an immunoconjugate containing described antibody. Disclosed is a method of treating cancer involving administering described antibody.EFFECT: invention widens range of agents for treating cancer.15 cl, 25 dwg, 16 tbl, 26 ex

Fcγriib-specific fc-antibody // 2608504
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is a polypeptide, comprising a Fc-domain of an antibody with at least one amino acid modification, which has high activity of binding with FcγRIIb in comparison with initial polypeptide, where value [value KD polypeptide containing Fc-domain of antibody against FcγRIIa (type R)]/[value KD polypeptide containing Fc-domain of antibody against FcγRIIb] is equal to or greater than 1.2, where value [value KD for higher activity of binding polypeptide containing Fc-domain of antibody against FcγRIIa (type R) and FcγRIIa (type H)]/[value KD for higher activity of binding initial polypeptide on FcγRIIa (type R) and FcγRIIa (type H)] is 0.7 or more, and where amino acid modification is a replacement of Pro in position 238 (EU numeration) with Asp or replacement of Leu in position 328 (EU numeration) with Glu. Described are methods of producing said polypeptide and use thereof.EFFECT: invention widens range of therapeutic and preventive agents.20 cl, 16 dwg, 12 tbl, 9 ex

New allergen // 2608494
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to novel horse allergens, and can be used in medicine for prophylactic or therapeutic treatment or diagnostics of type I allergy in horses. Horse allergen is obtained, which represents secretoglobin with molecular weight of 15 kDa in non-reducing conditions and contains first peptide chain with molecular weight of approximately 5 kDa and second peptide chain with molecular weight of approximately 10 kDa, linked to each other. Recombinant form of said allergen is also obtained.EFFECT: invention enables to obtain recombinant horse allergen with completely determined amino acid sequence.13 cl, 10 dwg, 3 tbl, 8 ex

Serotonin 5-ht3 receptor antagonists for application in treatment of lesional vestibular disorders // 2608458
FIELD: medicine.SUBSTANCE: invention relates to medicine and consists in application of serotonin 5-HT3 receptor antagonist for treatment of damages during vestibular disorders, wherein, mentioned damage is characterized by damage of internal ear cells and/or vestibular nerve cells, wherein, serotonin 5-HT3 receptor antagonist is selected from a group comprising ondansetron, palonosetron, tropisetron, lerisetron, alosetron, granisetron, dolasetron, bernesetron, ramosetron, azasetron, itasetron, zakoprid and cilansetron; and mentioned serotonin 5-HT3 receptor antagonist is introduced to the patient, at least during 5 days.EFFECT: treatment of damages during vestibular disorders.4 cl, 4 ex, 6 dwg
ethod of treating patients with x-linked agammaglobulinemia // 2608128
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to clinical immunology, and can be used for treating patients with X-linked agammaglobulinemia (X-AGG). For this patient gets replacement therapy of intravenous immunoglobulins. In addition from first day of treatment and every next six months after its start for first 10 days of each half of year patient gets 2 times day, in morning and evening, every 12 h oral administration of Polyoxidonium in dose of 12 mg.EFFECT: invention provides reduced number of infectious diseases in said category of patients due to recovery of adaptive capability of phagocytes.1 cl
Attenuated strain "msc-2015 vniivvim" of african swine fever virus serotype viii for virology and molecular-genetic analysis // 2607791
FIELD: medicine.SUBSTANCE: invention relates to virology. Attenuated strain “SKA-2015 VNIIVViM” of african swine fever virus serotype VIII is disclosed. Strain is produced by intermittent passages and selection of virulent strain "Stavropol 01/08" in primary cell culture of LS and transplantable hybrid cell line A4C2/9k and it is deposited in State collection of strains of microorganisms GNU Rosselhozakademii VNIIVViM under No. 1847.EFFECT: strain "MSC-2015 VNIIVViM" can be used during virological, molecular-genetic research, studying immunogenesis of disease, development of diagnostic and vaccine preparations.1 cl, 4 tbl, 4 ex
 
2550917.
Up!